BioCentury
ARTICLE | Company News

Auxilium to market Vivus' ED drug in U.S., Canada

October 12, 2013 12:12 AM UTC

Vivus Inc. (NASDAQ:VVUS) granted Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) exclusive rights to commercialize erectile dysfunction (ED) drug Stendra avanafil in the U.S. and Canada. Vivus will receive a $30 million license fee and is eligible for up to $270 million in milestones, plus tiered royalties. The fast-acting phosphodiesterase-5 (PDE-5) inhibitor is approved in the U.S. and is approved in Europe as Spedra. Vivus has rights to avanafil outside of Japan, China and certain other Pacific Rim countries from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508). ...